James Larkin

Royal Marsden NHS Foundation Trust

London

United Kingdom

SCHOLARLY PAPERS

3

DOWNLOADS

153

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (3)

1.

Collateral Damage: The Impact on Cancer Outcomes of the COVID-19 Pandemic

Number of pages: 29 Posted: 20 May 2020
Institute of Cancer Research (ICR) - Division of Genetics and Epidemiology, Institute of Cancer Research (ICR) - Division of Genetics and Epidemiology, Public Health England - National Cancer Registration and Analysis Service, Institute of Cancer Research (ICR) - Division of Genetics and Epidemiology, Institute of Cancer Research (ICR) - Division of Genetics and Epidemiology, Institute of Cancer Research (ICR) - Division of Genetics and Epidemiology, Royal Marsden NHS Foundation Trust - Urology Unit, Royal Marsden NHS Foundation Trust - Department of Anaesthesia, Oxford University Hospitals NHS Foundation Trust - Department of Colorectal Surgery, Royal Marsden NHS Foundation Trust - Department of Anaesthesia, Royal Marsden NHS Foundation Trust - Department of Anaesthesia, Royal Marsden NHS Foundation Trust - Lung Cancer Unit, Royal Marsden NHS Foundation Trust, Royal Marsden NHS Foundation Trust - Department of Clinical Oncology, Royal Marsden NHS Foundation Trust - RM Partners, University of Cambridge - Department of Public Health and Primary Care, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Imperial College Healthcare NHS Trust - Department of Clinical Oncology, Public Health England - National Cancer Registration and Analysis Service, Institute of Cancer Research (ICR) - Division of Genetics and Epidemiology and Institute of Cancer Research (ICR) - Division of Genetics and Epidemiology
Downloads 53 (414,643)

Abstract:

Loading...

cancer; diagnosis; surgery; COVID-19 pandemic; diagnostic delay; healthcare resource; life years gained; survival

2.

Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

Number of pages: 53 Posted: 17 Jun 2019
Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Sequencing Solutions, Institut de Cancérologie de Lorraine - Biopathology Service, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics, Royal Marsden Hospital, Royal Marsden Hospital, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, Roche Tissue Diagnostics, Roche Tissue Diagnostics, Roche Tissue Diagnostics, Roche Sequencing Solutions, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Aarhus University Hospital - Department of Molecular Medicine, Aarhus University Hospital - Department of Molecular Medicine, Aarhus University Hospital - Department of Molecular Medicine, Royal Marsden NHS Foundation Trust, University College London - Cancer Research UK Lung Cancer Centre of Excellence, Royal Marsden NHS Foundation Trust, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics and Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory
Downloads 52 (418,191)

Abstract:

Loading...

Tumor Sequencing, Molecular Profiling, Next Generation Sequencing, Cancer Genetics, Cancer Biomarkers

3.

Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301/Keynote-252 Study

The Lancet Oncology, VOLUME 20, ISSUE 8, P1083-1097, AUGUST 01, 2019, https://doi.org/10.1016/S1470-2045(19)30274-8
Number of pages: 39 Posted: 05 Feb 2019
The University of Sydney - Melanoma Institute Australia, University Hospital Zurich, Angeles Clinic and Research Institute, University of Chicago - Medical Center, Universidad del Desarrollo - Facultad de Medicina Clínica Alemana, University of Claude Bernard Lyon 1, Hospital Clinic of Barcelona, The University of Sydney - Melanoma Institute Australia, Aix-Marseille University, Seoul National University - Seoul National Hospital, N.N. Blokhin Russian Cancer Research Center, Université Paris XI Sud - Gustave Roussy Cancer Campus, Royal Marsden NHS Foundation Trust, Merck & Co., Inc., Incyte Corporation, Incyte Corporation, Merck & Co., Inc. and University of Pennsylvania - Abramson Family Cancer Research Institute
Downloads 48 (432,967)

Abstract:

Loading...

melanoma, indoleamine 2,3-dioxygenase, epacadostat, pembrolizumab, immunotherapy